T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells

Anthony M. Battram(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Carlos Fernández de Larrea(Hospital Clínic de Barcelona)
Molecular Therapy — Methods & Clinical Development
June 22, 2022
10.1016/j.omtm.2022.06.010
Cited by 12

Related Papers

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial
|Blood|2018|100
The Phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) Binder Rasa3 Regulates Phosphoinositide 3-kinase (PI3K)-dependent Integrin αIIbβ3 Outside-in Signaling
|Journal of Biological Chemistry|2016|44